Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate is taken up by abnormal skin cells and metabolised to protoporphyrin IX, a light‑sensitive compound. When the treated area is exposed to red light, the protoporphyrin generates reactive oxygen species that cause oxidative damage, leading to selective death of the targeted dysplastic cells while sparing normal tissue.

The specific dose and application regimen of Metvix are determined by the prescribing clinician based on lesion size, number, and location. Typically, a thin layer is applied to the lesion, covered for a defined incubation period, and then the area is illuminated with a calibrated red‑light source.

Safety data for Metvix in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

The primary alternative to Metvix is 5‑aminolevulinic acid (ALA) cream, such as Ameluz. Both are photosensitizers used for photodynamic therapy of actinic keratosis, but methyl aminolevulinate generally penetrates the skin more efficiently, allowing shorter incubation times. Choice of product depends on clinician preference, lesion characteristics and regulatory availability.

Metvix should be stored at room temperature, preferably below 25 °C, in its original packaging. The container should be kept closed to protect the cream from light, moisture and contamination. Do not freeze the product, and keep it out of reach of children.

Metvix is applied topically to the cleaned skin lesion as a thin, even layer. After a prescribed incubation period, the area is illuminated with a calibrated red‑light source (approximately 630 nm) for a specific duration. The treated skin is then cleaned, and normal post‑treatment care is followed.

Serious risks include ulceration of the treated site, secondary infection, severe photosensitivity reactions, and scarring. Patients should be instructed to monitor the area for excessive pain, persistent redness, or signs of infection and to seek medical attention promptly if such symptoms develop.

Metvix should not be used in individuals with known hypersensitivity to methyl aminolevulinate or any component of the formulation. It is also contraindicated in patients with active skin infections at the treatment site, in children for whom safety has not been established, and in pregnant or breastfeeding women unless the benefit outweighs the risk.